Skip links

About Us

Built on scientific excellence, guided by innovation, focused on patient impact

About MABPRO, a.s.

Cancer immunotherapy platform for hypoxic tumors

Our company was established in year 2016 as a spin – off from the Biomedical Research Center of Slovak Academy of Sciences.

Learn more

Headquartered in Bratislava, Slovak Republic, MABPRO, a.s. is building an immunotherapy platform for aggressive hypoxic tumors using carbonic anhydrase IX (CA IX) as a therapeutic target. CA IX enzyme has been scientifically proven to play a crucial role in cancer progression and aggressiveness, with possible impact on resistance of tumor cells to chemotherapy and radiotherapy, and thus is related with a poor prognosis for the patient.

MABPRO, a.s. has developed two humanized monoclonal antibodies (CA9hu-1 and CA9hu-2) with different mechanisms of action targeting CA IX that have already been pre-clinically proven to be efficient and safe. The greatest value of the unique MABPRO antibody CA9hu-1 is a dual action mode i.e. reversion of acidic tumor microenvironment and activating patient’s own immune system to destroy hypoxic tumor cells.

MABPRO, a.s. brings strong case for use as monotherapy as well as combined therapy.

Time and life-saving procedures: MABRO developed advanced patient stratification based on tissue samples, RNA sequencing and microtumors providing thorough protocol for healthcare providers to choose correct and efficient treatment for patients within a few weeks.

Advanced Patient Stratification

Tumor diagnostics

Pre-surgical biochemical and immunological analysis, post-surgical IHC analysis, RNA sequencing, and micro tumor preparation.

Analysis and machine learning

Collected data serve as a basis for individual characterization of tumors, including the genetic background, heterogeneity, and therapy sensitivity.

Effective therapy targeting

Identification of patients most likely to respond to our treatment is key to maximizing effectiveness and ensuring personalization.

Clinical and academic partners

A network of clinical sites working with experts in basic research, bioinformatics, and technology to support innovation and development.

Certificate

Development, production and distribution of biological organisms and materials, information, technology, intellectual property and standards for development, validation and application of scientific knowledge. Research and development in cancer immunotherapy.

See the certificate

Cancer Immunotherapy Platform For Hypoxic Tumors

Do you want to know more?

Personalized cancer immunotherapy for aggressive, hypoxic tumors with blockbuster potential

MABPRO, a.s. is building an immunotherapy platform and companion diagnostics for aggressive, hypoxic tumors using Carbonic Anhydrase IX (CA IX) as the therapeutic target and mechanism of action.

Extensive scientific literature, pre-clinical research and previous clinical studies confirm that targeting hypoxic tumors with CA IX can lead to highly effective immunotherapies for both solid and lymphomatic tumors.

Learn more

  • Our 5 initially targeted indications and sub-tumor types for which our compounds should work currently account for more than half of all cancer deaths.
  • Our business team includes highly experienced entrepreneurs and professionals in biopharma.
  • We have developed two core therapeutic assets – two humanized monoclonal antibodies targeting different cancer use-cases.
  • We have completed most of the pre-clinical work and are preparing to launch Phase I clinical trials.
  • We have built companion diagnostic and continue building advanced patient stratification protocols.
  • We hold comprehensive IP package related to CA IX-based therapies, including our own proprietary IP and an exclusive license for the entire core background IP related to therapeutic applications of CA IX (owned by the Slovak Academy of Sciences).
  • We have also started to explore the potential of our technology outside of cancer, starting with cardiovascular diseases.

Our Products Development Timeline

1

2016

Launching MABPRO, a.s.

MABPRO, a.s. holds an exclusive global license from BMC SAS for the CA IX patent portfolio, covering diagnostics, therapy, technology and know-how. The company is also licensed to develop new IP from the original rights, with full ownership of all resulting innovations and products.

2

2017 – 2018

MAB Humanization

MABPRO, a.s. has developed innovative biological drugs against CA IX, i.e. 25 humanized clones of murine monoclonal antibodies VII/20 and 25 humanized clones of murine monoclonal antibodies VII/18. It represents 50 variants of potential biological drugs.

3

2019

MAB Characterization

Characterization of 50 clones of humanized monoclonal antibodies (huMAbs) was done. Based on gained knowledge 2 huMabs has been chosen for further drug development process and commercialisation: CA9hu-1 and Ca9hu-2.

4

2019

Patent application

MABPRO is responsible for protecting the developed intellectual property. The unique sequences and properties of the CA9hu-1 and CA9hu-2 antibodies were included in the claims of two separate PCT patent applications. MABPRO, a.s. is the sole applicant in both cases. The applications were completed and filed under the Patent Cooperation Treaty (PCT) in 2019 and 2020, respectively.

5

2019

European Medical Agency

MABPRO, a.s. initiated pre-marketing authorisation procedures with the European Medicines Agency (EMA), including scientific advice and protocol assistance. As an EMA-registered SME, MABPRO benefits from a 90% fee reduction. The meeting was scheduled in Amsterdam for 30 September – 3 October 2019.

6

2023

SEAL of Excellence

Mabpro has been proudly recognised as a high-quality project proposal, standing out in a highly competitive evaluation process carried out by an international panel of independent experts. This recognition highlights the project’s excellence, innovation, and potential for significant impact.

Thank you for your support

Personalized immunotherapy for hypoxic tumors

Find Out More